PM
TGTX icon

Parametrica Management’s TG Therapeutics TGTX Stock Holding History

Parametrica Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26,402
Closed -$251K – 305
2022
Q1 		$251K Buy
+26,402
New +$306K 0.19% 153

Other funds holding TGTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parametrica Management's TGTX Position: Q2 2022 in Review

Parametrica Management sold out of TG Therapeutics (TGTX) in Q2 2022, closing a stake of 26,402 shares — an estimated $251K sold.

Parametrica Management first reported a position in TGTX in Q1 2022 and held it in 1 quarter. The position peaked at $251K in Q1 2022. 174 funds tracked by Wall St. Rank hold TGTX as of Q2 2022.

  • Parametrica Management reported no remaining TG Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Parametrica Management sold 26,402 TG Therapeutics shares in Q2 2022, an estimated $251K.
  • Parametrica Management first reported a position in TG Therapeutics in Q1 2022 and held it in 1 quarter.
  • Parametrica Management's TG Therapeutics position peaked at $251K in Q1 2022.
  • 174 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.